SOUTH SAN FRANCISCO, Calif., April 19, 2018 -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it will report first quarter financial results on Thursday, May 3, 2018, after the financial markets close.
Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call at 2:00 p.m. PT (5:00 p.m. ET) on May 3, 2018, to discuss first quarter 2018 financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call.
Individuals interested in listening to the conference call may do so by dialing (877) 556-5248 for domestic callers, or (720) 545-0029 for international callers. Please reference Conference ID 7270388. Interested parties may access the live teleconference in the Investors section of the company’s website at http://investors.fluidigm.com/events.cfm. The link will not be active until 1:45 p.m. PT (4:45 p.m. ET) on May 3, 2018.
A telephone replay of the teleconference will be available 90 minutes after the end of the call at (855) 859-2056 (domestic toll-free), or (404) 537-3406 (international toll), Conference ID 7270388. The conference call will also be archived on the Fluidigm Investors page at http://investors.fluidigm.com/.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm and the Fluidigm logo are trademarks or registered trademarks of Fluidigm Corporation.
Contact:
Fluidigm Corporation
Ana Petrovic
Director, Corporate Development and Investor Relations
650 243 6628
[email protected]


Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid
How Marco Pharma International Preserves German Homeopathic Traditions in America
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development
FTC Questions Apple News Over Alleged Bias Against Conservative Media
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 



